Ratings by Cantor Fitzgerald (Steven Seedhouse)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/1/2026 | Apellis Pharmaceuticals | APLS | Downgrade | Neutral (Overweight) |
17.09 (41.03) |
140.08% | Details | |
| 3/18/2026 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/16/2026 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/13/2026 | BioCryst Pharma | BCRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/13/2026 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/21/2025 | Pharvaris B.V. | PHVS | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/12/2025 | Astria Therapeutics | ATXS | Downgrade | Neutral (Overweight) |
12.51 (12.58) |
0.56% | Details | |
| 11/4/2025 | BioCryst Pharma | BCRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/23/2025 | Viking Therapeutic | VKTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/15/2025 | BioCryst Pharma | BCRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/13/2025 | Astria Therapeutics | ATXS | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/13/2025 | Pharvaris B.V. | PHVS | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/1/2025 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2025 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/24/2025 | Viking Therapeutic | VKTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/17/2025 | ProQR Therapeutics N.V. | PRQR | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/10/2025 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/27/2025 | ProQR Therapeutics N.V. | PRQR | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/14/2025 | Astria Therapeutics | ATXS | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/29/2025 | Inflarx NV | IFRX | New Coverage | Overweight (N/A) |
1.30 (2.06) |
58.46% | Details | |
| 4/29/2025 | ProQR Therapeutics N.V. | PRQR | New Coverage | Overweight (N/A) |
1.43 (1.47) |
2.8% | Details | |
| 4/29/2025 | Alnylam Pharmaceuticals | ALNY | New Coverage | Neutral (N/A) |
251.56 (292.58) |
16.31% | Details | |
| 4/29/2025 | Pharvaris B.V. | PHVS | New Coverage | Overweight (N/A) |
16.84 (30.14) |
78.98% | Details | |
| 4/29/2025 | BioCryst Pharma | BCRX | New Coverage | Overweight (N/A) |
8.39 (8.25) |
-1.67% | Details | |
| 4/29/2025 | Viking Therapeutic | VKTX | New Coverage | Overweight (N/A) |
24.99 (29.33) |
17.37% | Details | |
| 4/29/2025 | Apellis Pharmaceuticals | APLS | New Coverage | Overweight (N/A) |
17.49 (17.09) |
-2.29% | Details | |
| 4/29/2025 | Editas Medicine | ATXS | New Coverage | Overweight (N/A) |
1.54 (12.51) |
712.34% | Details |
